Discovery of FAP-Targeted Platinum(IV)-Esterified STING Agonist as Small-Molecule Dual Prodrug Conjugates for Tumor-Specific Metalloimmunotherapy.

Ende He, Jia Sun, Zhengyuan Wang, Yiming Fan, Zilan Song, Ao Zhang, Chunyong Ding

Abstract read

In one paragraph

Article in JACS Au, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it

0cells of the map it votes in

0citing papers in PubMed

–field-weighted citation impact

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Ende HeShanghai Frontiers Science Center of Drug Target Identification and Delivery, State Key Laboratory of Innovative Immunotherapy, School of Pharmaceutical Sciences, Shanghai Jiao Tong University, Shanghai 200240, China.

Jia SunShanghai Frontiers Science Center of Drug Target Identification and Delivery, State Key Laboratory of Innovative Immunotherapy, School of Pharmaceutical Sciences, Shanghai Jiao Tong University, Shanghai 200240, China.

Zhengyuan WangShanghai Frontiers Science Center of Drug Target Identification and Delivery, State Key Laboratory of Innovative Immunotherapy, School of Pharmaceutical Sciences, Shanghai Jiao Tong University, Shanghai 200240, China.

Yiming FanShanghai Frontiers Science Center of Drug Target Identification and Delivery, State Key Laboratory of Innovative Immunotherapy, School of Pharmaceutical Sciences, Shanghai Jiao Tong University, Shanghai 200240, China.

Zilan SongShanghai Frontiers Science Center of Drug Target Identification and Delivery, State Key Laboratory of Innovative Immunotherapy, School of Pharmaceutical Sciences, Shanghai Jiao Tong University, Shanghai 200240, China.

Ao ZhangShanghai Frontiers Science Center of Drug Target Identification and Delivery, State Key Laboratory of Innovative Immunotherapy, School of Pharmaceutical Sciences, Shanghai Jiao Tong University, Shanghai 200240, China.ORCID https://orcid.org/0000-0001-7205-9202

Chunyong DingShanghai Frontiers Science Center of Drug Target Identification and Delivery, State Key Laboratory of Innovative Immunotherapy, School of Pharmaceutical Sciences, Shanghai Jiao Tong University, Shanghai 200240, China.ORCID https://orcid.org/0000-0003-2379-8740

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Tumor-specific activation of the stimulator of the interferon genes (STING) pathway is essential for maximizing antitumor efficacy while minimizing systemic toxicity of STING agonists. Conjugating STING agonists with tumor-targeting warheads has emerged as a promising strategy in cancer immunotherapy. In this study, we designed and synthesized a series of fibroblast activation protein (FAP)-targeting platinum (Pt)-(IV)-centered STING agonist conjugates by esterifying the two axial hydroxyls of Pt-(IV) species with STING agonist

Indexed as

conjugateplatinum(IV) prodrugserine protease fibroblast activation proteinSTING activation

Identifiers

PMID42529290

DOI10.1021/jacsau.6c00442

PMCPMC13417285

What OpenQuestion holds

Textmetadata

LicenceCC BY-NC-ND

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.